138 related articles for article (PubMed ID: 37884538)
1. Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen.
Doss-Gollin S; Thomas S; Brook B; Abedi K; Lebas C; Auderset F; Lugo-Rodriguez Y; Sanchez-Schmitz G; Dowling DJ; Levy O; van Haren SD
NPJ Vaccines; 2023 Oct; 8(1):163. PubMed ID: 37884538
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine.
Atalis A; Keenum MC; Pandey B; Beach A; Pradhan P; Vantucci C; O'Farrell L; Noel R; Jain R; Hosten J; Smith C; Kramer L; Jimenez A; Ochoa MA; Frey D; Roy K
J Control Release; 2022 Jul; 347():476-488. PubMed ID: 35577151
[TBL] [Abstract][Full Text] [Related]
3. Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant.
Gray LT; Raczy MM; Briquez PS; Marchell TM; Alpar AT; Wallace RP; Volpatti LR; Sasso MS; Cao S; Nguyen M; Mansurov A; Budina E; Watkins EA; Solanki A; Mitrousis N; Reda JW; Yu SS; Tremain AC; Wang R; Nicolaescu V; Furlong K; Dvorkin S; Manicassamy B; Randall G; Wilson DS; Kwissa M; Swartz MA; Hubbell JA
Biomaterials; 2021 Nov; 278():121159. PubMed ID: 34634664
[TBL] [Abstract][Full Text] [Related]
4. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
[TBL] [Abstract][Full Text] [Related]
5. CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2.
Laotee S; Duangkaew M; Jivapetthai A; Tharakhet K; Kaewpang P; Prompetchara E; Phumiamorn S; Sapsutthipas S; Trisiriwanich S; Somsaard T; Roytrakul S; Duangkhae P; Ongpipattanakul B; Limpikirati P; Pornputtapong N; Arunmanee W
PLoS One; 2023; 18(7):e0288486. PubMed ID: 37450510
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine.
Atalis A; Keenum MC; Pandey B; Beach A; Pradhan P; Vantucci C; Jain R; Hosten J; Smith C; Kramer L; Jimenez A; Ochoa MA; Frey D; Roy K
bioRxiv; 2022 Feb; ():. PubMed ID: 35132413
[TBL] [Abstract][Full Text] [Related]
7. Bovine immune response to leptospira antigen in different novel adjuvants and vaccine delivery platforms.
Wilson-Welder JH; Boggiatto P; Nally JE; Wafa EI; Alt DP; Hornsby RL; Frank A; Jones DE; Olsen SC; Bowden NB; Salem AK
Vaccine; 2020 Apr; 38(18):3464-3473. PubMed ID: 32204939
[TBL] [Abstract][Full Text] [Related]
8. Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern.
Renner TM; Akache B; Stuible M; Rohani N; Cepero-Donates Y; Deschatelets L; Dudani R; Harrison BA; Baardsnes J; Koyuturk I; Hill JJ; Hemraz UD; Régnier S; Lenferink AEG; Durocher Y; McCluskie MJ
Front Immunol; 2023; 14():1182556. PubMed ID: 37122746
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondii.
Song P; He S; Zhou A; Lv G; Guo J; Zhou J; Han Y; Zhou H; Hao Z; Cong H
BMC Infect Dis; 2017 Jan; 17(1):19. PubMed ID: 28056837
[TBL] [Abstract][Full Text] [Related]
10. Foxp3+ CD4+ regulatory T cells control dendritic cells in inducing antigen-specific immunity to emerging SARS-CoV-2 antigens.
Uraki R; Imai M; Ito M; Shime H; Odanaka M; Okuda M; Kawaoka Y; Yamazaki S
PLoS Pathog; 2021 Dec; 17(12):e1010085. PubMed ID: 34882757
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of SARS-CoV-2 Trimeric Spike Protein Associated to Poly(I:C) Plus Alum.
Dos-Santos JS; Firmino-Cruz L; da Fonseca-Martins AM; Oliveira-Maciel D; Perez GG; Roncaglia-Pereira VA; Dumard CH; Guedes-da-Silva FH; Santos ACV; Leandro MDS; Ferreira JRM; Guimarães-Pinto K; Conde L; Rodrigues DAS; Silva MVM; Alvim RGF; Lima TM; Marsili FF; Abreu DPB; Ferreira OC; Mohana Borges RDS; Tanuri A; Souza TML; Rossi-Bergmann B; Vale AM; Silva JL; de Oliveira AC; Filardy AD; Gomes AMO; de Matos Guedes HL
Front Immunol; 2022; 13():884760. PubMed ID: 35844561
[TBL] [Abstract][Full Text] [Related]
12. Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review.
Lacaille-Dubois MA
Phytomedicine; 2019 Jul; 60():152905. PubMed ID: 31182297
[TBL] [Abstract][Full Text] [Related]
13. Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunity.
Volpatti LR; Wallace RP; Cao S; Raczy MM; Wang R; Gray LT; Alpar AT; Briquez PS; Mitrousis N; Marchell TM; Sasso MS; Nguyen M; Mansurov A; Budina E; Solanki A; Watkins EA; Schnorenberg MR; Tremain AC; Reda JW; Nicolaescu V; Furlong K; Dvorkin S; Yu SS; Manicassamy B; LaBelle JL; Tirrell MV; Randall G; Kwissa M; Swartz MA; Hubbell JA
bioRxiv; 2021 Apr; ():. PubMed ID: 33851166
[TBL] [Abstract][Full Text] [Related]
14. Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity.
Volpatti LR; Wallace RP; Cao S; Raczy MM; Wang R; Gray LT; Alpar AT; Briquez PS; Mitrousis N; Marchell TM; Sasso MS; Nguyen M; Mansurov A; Budina E; Solanki A; Watkins EA; Schnorenberg MR; Tremain AC; Reda JW; Nicolaescu V; Furlong K; Dvorkin S; Yu SS; Manicassamy B; LaBelle JL; Tirrell MV; Randall G; Kwissa M; Swartz MA; Hubbell JA
ACS Cent Sci; 2021 Aug; 7(8):1368-1380. PubMed ID: 34466656
[TBL] [Abstract][Full Text] [Related]
15. A liposomal vaccine promotes strong adaptive immune responses via dendritic cell activation in draining lymph nodes.
Agallou M; Margaroni M; Tsanaktsidou E; Badounas F; Kammona O; Kiparissides C; Karagouni E
J Control Release; 2023 Apr; 356():386-401. PubMed ID: 36893900
[TBL] [Abstract][Full Text] [Related]
16. Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses.
Tukhvatulin AI; Dzharullaeva AS; Tukhvatulina NM; Shcheblyakov DV; Shmarov MM; Dolzhikova IV; Stanhope-Baker P; Naroditsky BS; Gudkov AV; Logunov DY; Gintsburg AL
PLoS One; 2016; 11(5):e0155650. PubMed ID: 27187797
[TBL] [Abstract][Full Text] [Related]
17. Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2.
Jung HE; Ku KB; Kang BH; Park JH; Kim HC; Kim KD; Lee HK
Antiviral Res; 2023 Aug; 216():105656. PubMed ID: 37327877
[TBL] [Abstract][Full Text] [Related]
18. TLR9 and STING agonists cooperatively boost the immune response to SARS-CoV-2 RBD vaccine through an increased germinal center B cell response and reshaped T helper responses.
Yang JX; Tseng JC; Tien CF; Lee CY; Liu YL; Lin JJ; Tsai PJ; Liao HC; Liu SJ; Su YW; Hsu LC; Chen JK; Huang MH; Yu GY; Chuang TH
Int J Biol Sci; 2023; 19(9):2897-2913. PubMed ID: 37324951
[TBL] [Abstract][Full Text] [Related]
19. Enhancing Immunogenicity of a Thermostable, Efficacious SARS-CoV-2 Vaccine Formulation through Oligomerization and Adjuvant Choice.
Khan MS; Jakob V; Singh R; Rajmani RS; Kumar S; Lemoine C; Kleanthous H; Ringe RP; Dubois PM; Varadarajan R
Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140101
[TBL] [Abstract][Full Text] [Related]
20. A COVID-19 vaccine candidate based on SARS-CoV-2 spike protein and immune-stimulating complexes.
Villarraza J; Fuselli A; Gugliotta A; Garay E; Rodríguez MC; Fontana D; Antuña S; Gastaldi V; Battagliotti JM; Tardivo MB; Alvarez D; Castro E; Cassataro J; Ceaglio N; Prieto C
Appl Microbiol Biotechnol; 2023 Jun; 107(11):3429-3441. PubMed ID: 37093307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
